Meghan Sise, MD
Nephrology · Boston, MANPI 1003043571
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 44.2% of the total. Reporting peaked in 2024 at $69,982 and has fallen 70.7% since, to $20,516 in 2025. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $2630.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$50K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$24K
- Novartis$14K
- Gilead$9K
- Travere Therapeutics, Inc.$7K
- Vertex$5K
- plus $4K from 2 others
Across 84 payments — averaging $12,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$527K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$295K
- Merck$53K
- Novartis$52K
- Astrazeneca UK Limited$37K
- Hoffmann-la Roche Limited$28K
- plus $55K from 3 others
What the payments were for
- Consulting fees$60,41553%
- Grants$50,00044%
- Travel & lodging$1,8252%
- Food & beverage$8501%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $50,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $24,455 |
| Novartis | 8 | $14,159 |
| Gilead | 13 | $8,704 |
| Travere Therapeutics, Inc. | 5 | $6,503 |
| Vertex | 2 | $5,000 |
| Calliditas Therapeutics US Inc. | 2 | $2,152 |
| Mallinckrodt Hospital Products Inc. | 1 | $2,120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,093 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 13 | $19,411 |
| Torsemide | 47 | $1,357 |
| Amlodipine Besylate | 49 | $385 |
| Carvedilol | 20 | $365 |
| Famotidine | 30 | $301 |
| Irbesartan | 22 | $257 |
| Tamsulosin Hcl | 15 | $239 |
| Lisinopril | 21 | $156 |
| Furosemide | 20 | $92 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boston
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Leslie FangBoston$388K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
- Andrew AllegrettiBoston$139K
- Ravi ThadhaniBoston$115K
- Ronald PerroneBoston$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.